150 Ces Urol 2023; 27(3): 139-150 PŘEHLEDOVÉ ČLÁNKY 46. Xu B, Wang C, Wang YL, et al. miR-143 inhibits renal cell carcinoma cells metastatic potential by supp‑ ressing ABL2. Kaohsiung Journal of Medical Sciences. 2020; 36(8): 592–8. 47. Seles M, Hutterer G, Kiesslich T, et al. Current Insights into Long Non‑Coding RNAs in Renal Cell Car‑ cinoma. International Journal of Molecular Sciences. 2016; 17(4): 573. 48. Wang W, Song J, Zhang W, et al. Identification of Long Non‑Coding RNA Signatures for Specific Disease‑Free Prognosis in Clear Cell Renal Carcinoma. IEEE Access. 2019; 7: 99290–8. 49. Qu L, Wang ZL, Chen Q, et al. Prognostic Value of a Long Non‑coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. European Urology. 2018; 74(6): 756–63. 50. Guan Y, Xu F, Tian J, et al. The prognostic value of circulating tumour cells (CTCs) and CTC white blood cell clusters in patients with renal cell carcinoma. BMC Cancer. 2021; 21(1). 51. Broncy L, Paterlini‑Bréchot P. Circulating Tumor Cells for the Management of Renal Cell Carcinoma. Diagnostics. 2018; 8(3): 63. Hotel Vienna House Andel’s, Stroupežnického 21, Praha 5 Pořadatel a organizátor 17.– 18. 5. 2024 9. ROČNÍK KOMPLEXNÍ NOVINKY V ONKOUROLOGII KNOU2024
RkJQdWJsaXNoZXIy NDA4Mjc=